HBV DNA is an accurate indicator of viral replication, and the latest U.S. Guidelines for the Treatment of Hepatitis B point out that patients with HBV cirrhosis, whether in the compensated or decompensated stage, need to consider antiviral therapy as long as the HBV DNA in the body is measurable. Some foreign scholars even advocate that patients with HBV cirrhosis in the decompensated stage should be treated with antiviral therapy, regardless of HBV DNA positive or negative, so as to obtain continuous viral suppression and reduce the necroinflammation of the liver.